Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs

Sormani, M. P.; Bonzano, L.; Roccatagliata, L.; De Stefano, N.
May 2011
Multiple Sclerosis Journal;May2011, Vol. 17 Issue 5, p630
Academic Journal
Recent studies have provided evidence for using magnetic resonance imaging (MRI) active lesions as surrogate for relapses and disability progression in multiple sclerosis (MS). However, the validity of MRI metrics as surrogate endpoints in MS is controversial. Furthermore, the extrapolation of previous results to novel therapies is not warranted. We tested here the validity of MRI surrogacy in MS studies on recently published trials of oral drugs. The 92% of observed effects of oral drugs on clinical outcomes resulted close to those predicted by MRI active lesions. This further validates MRI surrogacy in MS, with important implications for future trials planning.


Related Articles

  • Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Sormani, Maria Pia; Stubinski, Bettina; Cornelisse, Peter; Rocak, Sanda; Li, David; Stefano, Nicola De // Multiple Sclerosis Journal;May2011, Vol. 17 Issue 5, p541 

    Background: Use of quantitative magnetic resonance imaging (MRI) metrics as surrogates for clinical outcomes in multiple sclerosis (MS) trials is controversial.Objectives: We sought to validate, at the individual-patient level, the number of MRI active lesions, as a surrogate marker for relapses...

  • Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Nelson, Flavia; Datta, Sushmita; Garcia, Nereyda; Rozario, Nigel L.; Perez, Francisco; Cutter, Gary; Narayana, Ponnada A.; Wolinsky, Jerry S. // Multiple Sclerosis Journal;Sep2011, Vol. 17 Issue 9, p1122 

    Background: Accurate classification of multiple sclerosis (MS) lesions in the brain cortex may be important in understanding their impact on cognitive impairment (CI). Improved accuracy in identification/classification of cortical lesions was demonstrated in a study combining two magnetic...

  • Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: A preliminary study. Yunyan Zhang; Traboulsee, Anthony; Yinshan Zhao; Metz, Luanne M.; Li, David K. // Multiple Sclerosis Journal;May2011, Vol. 17 Issue 5, p532 

    Background and Objective: The persistence of new enhancing T1 hypointense lesions (acute black holes, ABHs) in multiple sclerosis (MS) cannot be predicted visually at lesion onset. Texture analysis using the polar Stockwell transform (PST) applied to conventional MR images however shows promise...

  • Prediction of long-term disability in multiple sclerosis. Schlaeger, R; D’Souza, M; Schindler, C; Grize, L; Dellas, S; Radue, EW; Kappos, L; Fuhr, P // Multiple Sclerosis Journal;Jan2012, Vol. 18 Issue 1, p31 

    Background: Little is known about the predictive value of neurophysiological measures for the long-term course of multiple sclerosis (MS).Objective: To prospectively investigate whether combined visual (VEP) and motor evoked potentials (MEP) allow prediction of disability over 14 years.Methods:...

  • Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p80 

    In this article the author discusses a study on the effectiveness of natalizumab with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis (RRMS). It is based on the 2-year magnetic resonance imaging (MRI) data from the Safety and Efficacy of Natalizumab in Combination...

  • MRI-based clinical trials in relapsing–remitting MS: new sample size calculations based on a longitudinal model. Altman, RM; Petkau, AJ; Vrecko, D; Smith, A // Multiple Sclerosis Journal;Nov2012, Vol. 18 Issue 11, p1600 

    The article presents research that evaluates the appropriateness of the negative binomial (NB) model for the lesion count data of magnetic resonance imaging (MRI)-based clinical trials in relapsing-remitting multiple sclerosis (MS). The study shows that longitudinal model-based sample sizes are...

  • Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity. Bates, David; Bartholomé, Emmanuel // Journal of Neurology, Neurosurgery & Psychiatry;Jan2012, Vol. 83 Issue 1, p55 

    Natalizumab treatment significantly reduced the annualised relapse rate and MRI activity over 2 years compared with placebo in phase III trials when administered as monotherapy in AFFIRM or in combination with interferon β-1a (IFNβ) in SENTINEL. The post hoc analyses reported here...

  • The what's and why's of clinical trials. Reingold, Stephen // Inside MS;Winter/Spring95, Vol. 13 Issue 1, p4 

    Focuses on the mechanics of clinical trials in the study of multiple sclerosis (MS). Features of a clinical trial include unpredictability; Difference in effect of different agents on various types of MS; Effect of motivation to treatment; Phases of a clinical trial; Criteria for enrolling in...

  • Does MRI lesion activity regress in secondary progressive multiple sclerosis? Zhao, Y.; Petkau, A. J.; Traboulsee, A.; Riddehough, A.; Li, D. K. B. // Multiple Sclerosis (13524585);Apr2010, Vol. 16 Issue 4, p434 

    Background: The rate of new contrast-enhancing lesions (CELs) on monthly magnetic resonance imaging (MRI) scans has been shown to decrease over a 9-month period in placebo-treated patients with relapsing-remitting (RR) multiple sclerosis (RRMS). Objective: We examined this phenomenon in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics